AACR 2023: A tailored platform enables BRAF-targeted drug discovery and precision medicine

In our latest AACR poster, WuXi AppTec scientists showcase the development of a tailored platform of patient-derived xenograft (PDX) models based on the classification of BRAF mutations. This panel covers all 3 classes of BRAF mutants, including subtypes for which viable therapeutic options remain limited. The authors demonstrate that these PDX models are responsive to BRAF and/or MEK inhibition.
Check out our comprehensive panel of PDX models

4988_A tailored platform enables BRAF-targeted drug discovery and precision medicine_final - Copy
Related Content
Mutant p53 is one of the most attractive targets for new anti-cancer drugs. Although traditionally regarded as difficult to drug,...
VIEW RESOURCEWith advancements in drug design, there is resurging interest in drugs that form covalent bonds with their targets, often referred...
VIEW RESOURCE